, Tracking Stock Market Picks
Enter Symbol:
Rating: RMD
up 11.00 %

Resmed Inc. (NYSE: RMD) downgraded to Neutral by BofA/Merrill

Wednesday,  May 13, 2015  10:25 AM ET by Dave Ficere

BofA/Merrill downgraded Resmed Inc. (NYSE: RMD) to Neutral. Previously BofA/Merrill rated Buy Resmed Inc. (NYSE: RMD) on 08/26/2013, when the
stock price was $49.65. Since then, Resmed Inc.'s stock price has gained 11% as of 05/13/2015's recent price of $55.25.
If you would have followed the previous BofA/Merrill's recommendation on RMD, you would have gained 11% of your investment in 625 days.

ResMed Inc. is a holding company. Through its subsidiaries, the Company develops, manufactures and distributes medical equipment for treating, diagnosing and managing sleep-disordered breathing (SDB) and other respiratory disorders, including obstructive sleep apnea (OSA). It has developed nasal continuous positive airway pressure (CPAP) as a non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. The Company has developed a number of products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. ResMed Inc. sells its products in over 70 countries through a combination of wholly owned subsidiaries and independent distributors to sleep clinics, home healthcare dealers and third-party payers. On April 30, 2009, it acquired Respicure Medsys PVT.LTD. In October 2009, ResMed Inc. acquired Laboratoires Narval.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy